82 related articles for article (PubMed ID: 18606594)
1. Oral vinorelbine as first line chemotherapy in unfit elderly patients with hormone-refractory prostate cancer.
Caristi N; Maisano R; Iorfida M; Scimone A; Lupo G; Buda C; Scisca C; Adamo V
J Chemother; 2008 Jun; 20(3):368-73. PubMed ID: 18606594
[TBL] [Abstract][Full Text] [Related]
2. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
Mackler NJ; Dunn RL; Hellerstedt B; Cooney KA; Fardig J; Olson K; Pienta KJ; Smith DC
Cancer; 2006 Jun; 106(12):2617-23. PubMed ID: 16691618
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of vinorelbine and estramustine in the treatment of metastatic hormone-resistant prostate cancer.
Borrega P; Velasco A; Bolaños M; del Mar Perez M; Mel JR; Reina JJ; Rodríguez-Jaraiz MA; Chaves M; González-Barón M
Urol Oncol; 2004; 22(1):32-5. PubMed ID: 14969801
[TBL] [Abstract][Full Text] [Related]
4. Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer.
Abratt RP; Brune D; Dimopoulos MA; Kliment J; Breza J; Selvaggi FP; Beuzeboc P; Demkow T; Oudard S
Ann Oncol; 2004 Nov; 15(11):1613-21. PubMed ID: 15520061
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer.
Colleoni M; Graiff C; Vicario G; Nelli P; Sgarbossa G; Pancheri F; Manente P
Am J Clin Oncol; 1997 Aug; 20(4):383-6. PubMed ID: 9256895
[TBL] [Abstract][Full Text] [Related]
6. Weekly docetaxel and vinorelbine (VIN-DOX) as first line treatment in patients with hormone refractory prostate cancer.
Di Lorenzo G; Pizza C; Autorino R; De Laurentiis M; Marano O; D'Alessio A; Cancello G; Altieri V; Tortora G; Perdonà S; Bianco AR; De Placido S
Eur Urol; 2004 Dec; 46(6):712-6. PubMed ID: 15548437
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of vinorelbine in patients with androgen-independent prostate cancer.
Oudard S; Caty A; Humblet Y; Beauduin M; Suc E; Piccart M; Rolland F; Fumoleau P; Bugat R; Houyau P; Monnier A; Sun X; Montcuquet P; Breza J; Novak J; Gil T; Chopin D
Ann Oncol; 2001 Jun; 12(6):847-52. PubMed ID: 11484963
[TBL] [Abstract][Full Text] [Related]
8. [Intravenous vinorelbine as first line chemotherapy in patients with castration-resistant prostate cancer].
Grenader T; Plotkin Y; Rosengarten O
Harefuah; 2014 Dec; 153(12):731-4, 752. PubMed ID: 25654915
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study.
Di Lorenzo G; Autorino R; Perdonà S; De Laurentiis M; D'Armiento M; Cancello G; Mirone V; Imbimbo C; Longo N; Altieri V; Tortora G; Figg WD; De Placido S
Eur Urol; 2007 Oct; 52(4):1020-7. PubMed ID: 17360103
[TBL] [Abstract][Full Text] [Related]
10. Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer.
Nelius T; Reiher F; Lindenmeir T; Klatte T; Rau O; Burandt J; Filleur S; Allhoff EP
Onkologie; 2005 Nov; 28(11):573-8. PubMed ID: 16249643
[TBL] [Abstract][Full Text] [Related]
11. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer.
Borden LS; Clark PE; Lovato J; Hall MC; Stindt D; Harmon M; M Mohler R; Torti FM
Cancer; 2006 Sep; 107(5):1093-100. PubMed ID: 16888761
[TBL] [Abstract][Full Text] [Related]
12. Combination chemotherapy with docetaxel, vinorelbine and estramustine phosphate in metastatic androgen-resistant prostate cancer: a single institution experience.
Pectasides D; Pectasides E; Papaxoinis G; Koumarianou A; Psyrri A; Xiros N; Tountas N; Kamposioras K; Papatsibas G; Floros T; Gouveris P; Karageorgopoulou S; Economopoulos T
Anticancer Res; 2009 Feb; 29(2):769-75. PubMed ID: 19331234
[TBL] [Abstract][Full Text] [Related]
13. Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a phase II study.
Smith MR; Kaufman D; Oh W; Guerin K; Seiden M; Makatsoris T; Manola J; Kantoff PW
Cancer; 2000 Oct; 89(8):1824-8. PubMed ID: 11042579
[TBL] [Abstract][Full Text] [Related]
14. Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure.
Ladoire S; Eymard JC; Zanetta S; Mignot G; Martin E; Kermarrec I; Mourey E; Michel F; Cormier L; Ghiringhelli F
Anticancer Res; 2010 Oct; 30(10):4317-23. PubMed ID: 21036758
[TBL] [Abstract][Full Text] [Related]
15. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
Oudard S; Banu E; Beuzeboc P; Voog E; Dourthe LM; Hardy-Bessard AC; Linassier C; Scotté F; Banu A; Coscas Y; Guinet F; Poupon MF; Andrieu JM
J Clin Oncol; 2005 May; 23(15):3343-51. PubMed ID: 15738542
[TBL] [Abstract][Full Text] [Related]
16. Vinorelbine and prednisone in older cancer patients with hormone-refractory metastatic prostate cancer. A phase II study.
Tralongo P; Bollina R; Aiello R; Di Mari A; Moruzzi G; Beretta G; Mauceri G; Conti G
Tumori; 2003; 89(1):26-30. PubMed ID: 12729357
[TBL] [Abstract][Full Text] [Related]
17. A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer.
Lin CC; Hsu CH; Chen J; Tsai TC; Cheng AL; Pu YS
Anticancer Res; 2001; 21(2B):1385-90. PubMed ID: 11396219
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of vinorelbine with low dose prednisone in the treatment of hormone-refractory metastatic prostate cancer.
Robles C; Furst AJ; Sriratana P; Lai S; Chua L; Donnelly E; Solomon J; Sundaram M; Feun L; Savaraj N
Oncol Rep; 2003; 10(4):885-9. PubMed ID: 12792740
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel-based chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: factors predicting response and survival.
Nayyar R; Sharma N; Gupta NP
Int J Urol; 2009 Sep; 16(9):726-31. PubMed ID: 19769656
[TBL] [Abstract][Full Text] [Related]
20. Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer.
Addeo R; Sgambato A; Cennamo G; Montella L; Faiola V; Abbruzzese A; Capasso E; Leo L; Botti G; Caraglia M; Del Prete S
Clin Breast Cancer; 2010 Aug; 10(4):301-6. PubMed ID: 20705563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
